



ISSN (P): 2617-7226  
ISSN (E): 2617-7234  
[www.patholjournal.com](http://www.patholjournal.com)  
2020; 3(1): 428-431  
Received: 02-11-2019  
Accepted: 04-12-2019

**Dr. Somil Singhal**  
Consultant Pathologist, Kriti  
Pathology (A Complete  
Diagnostic Solution)  
A Unit of Kriti Scanning  
Centre (P) Ltd. Allahabad,  
Uttar Pradesh, India

## A case of chronic myeloid leukemia with Philadelphia chromosome, BCR-ABL transcript and complex translocation involving four different chromosomes

**Dr. Somil Singhal**

**DOI:** <https://doi.org/10.33545/pathol.2020.v3.i1g.205>

### Abstract

Such reported cases with the e13a3 transcript showed the Ph chromosome on karyotype analysis. This study reported a rare Ph chromosome-positive CML case with new complex chromosomal aberrations and an e13a3 BCR-ABL transcript that has yet to be established. A four-chromosome translocation involving chromosomal regions 12p11.2, 19q13.3, 9q34.1 and 22q11.2, besides a trisomy 8 and a derivative chromosome 12, were identified using high resolution multicolor banding. Reverse transcription polymerase chain reaction products showed the presence of BCR-ABL fusion transcript e13a3, and this signifies the major BCR breakpoint. The significance of the observed rearrangements and their possible role in the progression of CML was investigated.

**Keywords:** chronic myeloid leukemia, Philadelphia chromosome, e13a3, fluorescence in situ hybridization, high resolution multicolor banding, reverse transcription polymerase chain reaction

### Introduction

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the expansion of a clone of pluripotent hematopoietic stem cells carrying the chimeric BCR-ABL fusion gene. The Philadelphia (Ph) chromosome created as a result of t(9;22) (q34;q11) is observed in more than 90% of CML patients. The BCR-ABL fusion gene is formed by transposing the 3' portion of the ABL oncogene from 9q34 to the 5' portion of the BCR gene on chromosome 22, and this fusion gene encodes a constitutive active tyrosine kinase [1]. BCR breakpoints localize on 1 of 3 breakpoint cluster regions (bcr): major bcr spanning BCR exons 12-16, minor bcr spanning BCR alternative exons 2' and 2 and  $\mu$ bcr spanning downstream of exon 19. The majority of the BCR-ABL fusion transcripts are e13a2, e14a2, with e1a2 and e19a2 being less common [2]. Cases reported to have the e13a3 transcript showed the Ph chromosome on karyotype analysis. A cryptic or variant rearrangement in which the typical Ph chromosome is not visible at the karyotype level is noted in 5-10% of CML patients [3-6]. This rearrangement can be found in cases of normal or complex karyotypes. The mechanisms for these rearrangements are difficult to determine. This study reported a rare Ph chromosome-positive CML case involving the e13a3 BCR-ABL transcript and new complex aberrations, including four chromosomal breakpoints.

### Materials and methods

#### Case report

A 36-year-old female was diagnosed as CML accelerated phase (AP), hepatosplenomegaly and loss of weight was predominant finding. The hematologic parameters were: white blood cells (WBC)  $132 \times 10^9 / l$  (96.6% polymorphs, 1.55% lymphocytes, 0.170% monocytes, 1.68% eosinophils and 0.04% basophils). The platelet count was  $196 \times 10^9 / l$  and the hemoglobin level was 9.3 g/dl. The patient was referred to our laboratory after treatment with Imatinib. Therefore, the previous relevant symptoms were disappeared. The more recent hematological parameters were: WBC  $6.5 \times 10^9 / l$  (42.9% neutrophils, 44.1% lymphocytes and 13% monocytes). The platelet count was  $475 \times 10^9 / l$  and the hemoglobin level was 11.9 g/dl.

#### Banding cytogenetics

Chromosome analysis was performed using the GTG-banding technique according to

**Corresponding Author:**  
**Dr. Somil Singhal**  
Consultant Pathologist, Kriti  
Pathology (A Complete  
Diagnostic Solution)  
A Unit of Kriti Scanning  
Centre (P) Ltd. Allahabad,  
Uttar Pradesh, India

standard procedures [7]. A total of 20 metaphases, obtained from the stimulated bone marrow of the patient, were analyzed. Karyotypes were described according to the

International System for Human Cytogenetic Nomenclature [8].



**Fig 1:** GTG-banding revealed a complex karyotype involving two further chromosomes besides chromosomes 9 and 22. Derivative chromosomes are indicated by the arrowheads.

### Molecular cytogenetics

Fluorescence in situ hybridization (FISH) using a LSI BCR/ABL dual color dual fusion translocation probe was applied according to the manufacturer's instructions. Array-proven multicolor banding (aMCB) probe sets based on micro dissection-derived region-specific libraries for chromosomes 9, 12, 19 and 22 were applied as previously described [9, 10]. A total of 20 metaphase spreads were analyzed. Image capturing and processing were carried out using an Isis imaging system for the MCB evaluation.

### RNA isolation and reverse transcriptase-polymerase chain reaction.

Total RNA was extracted from 1.5 ml of fresh peripheral blood immediately after collection using the ThermoFisher RNA kit. A negative control was used to monitor RNA isolation. RNA concentration was estimated by absorbance at 260 nm and its purification was determined by a 1.8:2.0 ratio of absorbance values at 260:280 nm. The RNA solutions were stored at -80 °C. Reverse transcription (RT) for the complementary DNA (cDNA) synthesis, polymerase chain reaction (PCR) and nested PCR amplification of the BCR-ABL gene were performed using a ready-to-use Genequality BCR-ABL kit and a GeneAmp® PCR System 9700 thermocycler. Two positive controls were used to monitor amplification, one with  $\beta$ 2-microglobuline and the second b3a2 with the patient sample. The negative controls used serial water. PCR products were electrophoresed on an ethidium bromide-stained 2.5% agarose-TAE-gel and observed under UV light. The type of amplified BCR/ABL


cDNA was established on the basis of the size compared with the molecular markers and the primers used (b3a2, 353 bp; b2a2, 278 bp; b3a3, 179 bp and b2a3 (e13a3), 104 bp).

### Results

Karyotyping was performed before and after the initiation of chemotherapy treatment, showing the following karyotypic changes: a complex karyotype 48,XX,+8,+der(12)t(12;19),t(9;12;19;22)/47,XX,+8,t(9;12;19;22)/47,XX,+der(12)t(12;19),t(9;12;19;22)/46,XX,t(9;12;19;22) was determined using GTG-banding (Fig. 1) and was further specified by molecular cytogenetic studies (Fig. 2). A dual-color-FISH using a probe specific for BCR and ABL showed a typical Ph chromosome with a BCR/ABL fusion gene. However, sections of chromosome 22 were present on a der(19) (Fig. 2F). A multi-color (M)-FISH, was applied to exclude further cryptic rearrangements (Fig. 2A). Thus, the four chromosomes 9, 12, 19 and 22 were found to be involved. aMCB using probes for the corresponding chromosomes were performed as previously reported [11]. A complex translocation among the four chromosomes was detected (Figs. 2B-E), and the following final karyotypes were obtained:


48,XX,+8,+der(12)t(12;19)(p11.2;q13.3),t(9;12;19;22)(q34.1;p11.2;q13.3;q11.2)[8]/47,XX,8,t(9;12;19;22)(q34.1;p11.2;q13.3;q11.2)[2]/47,XX,+der(12)t(12;19)(p11.2;q13.3),t(9;12;19;22)(q34.1;p11.2;q13.3;q11.2)[2]/46,XX,t(9;12;19;22)(q34.1;p11.2;q13.3;q11.2)[8].

It is likely that due to low chromosomal resolution, the complexity of the karyotype was initially missed. RT-PCR analysis of the fusion transcript showed a band corresponding to the e13a3 (b2-a3) transcript. However, the band was ~104 bp (Fig. 3).



**Fig 2:** Karyotype and chromosomal aberrations were confirmed using molecular cytogenetic approaches. (A) M-FISH confirmed the complexity of the karyotype: 48,XX,+8,+der(12),t(9;12),t(12;19),t(19;22). (B-E) The application of aMCB analysis using probe sets for chromosomes 9, 12, 19 and 22 is shown. The normal chromosomes are shown to the left of the image, and the derivative of the four chromosomes to the middle and right. Using aMCB probes, the light gray areas show unstained regions on the derivative chromosomes. (F) Fluorescence in situ hybridization (FISH) using probes for

BCR (green) and ABL (red) confirmed the involvement of chromosome 19 in the rearrangement present in this case.#, chromosome; der, derivative chromosome; Ph, Philadelphia chromosome.



**Fig 3:** Gel electrophoresis of the nested RT-PCR products. Lane M, 501-110 bp marker; lane 1, negative control; lane 2, positive control (b3a2, 353 bp); lane 3,  $\beta$ 2-microglobuline (535 bp); lane 4, BCR-ABL (b2a3, 104 bp) from the patient and lane 5, M/4100 bp molecular weight marker.

**Discussion**

A Case of rare Ph chromosome-positive CML with the e13a3 BCR-ABL transcript and a new complex variant translocation t(9;12;19;22)(q34.1;p11.2;q13.3;q11.2) that was detected. Apart from a trisomy 8 and an additional derivative chromosome 12, two additional chromosomal alterations were present. To the best of my knowledge, this translocation has yet to be elucidated in CML [12]. In 5-10% of Ph chromosome CML cases complex translocations in addition to those and/or besides chromosomes 9 and 22 [13] are noted. At present it appears that in such rearrangements any other chromosome may be involved. However, it has been suggested that the distribution of chromosomes and breakpoints is non-random with the chromosomal bands most susceptible to breakage being 1p36, 3p21, 5q31, 6p21, 9q22, 10q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12 and 22q13 [6], showing one match with the present case, i.e., 19q13. The progression of CML from AP to blast crisis is frequently associated with non-random secondary chromosomal aberrations such as +8, i(17q), +19 and an extra Ph chromosome [14]. Trisomy 12 is the most frequently reported chromosome abnormality in B-cell chronic lymphocytic leukemia (B-CLL). It is found in one third of cytogenetically abnormal CLL by conventional karyotype [15] and in approximately 11-46% of cases when interphase FISH is used [16]. The majority of CML patients express e13a2 (b2-a2) or e14a2 (b3-a2) of BCR-ABL mRNA encoding for p210 Bcr-Abl tyrosine kinase. These two types are detected by RT-PCR [17-19]. CML with the e13a3 transcript is extremely rare, and RT-PCR for e13a2 and e14a2 is usually negative because ABL exon 2 is deleted [20]. This case was diagnosed using conventional G-band, FISH, M-FISH, MCB and RT-PCR.

In conclusion, we reported a rare Ph chromosome-positive CML case in CP with the rare e13a3 BCR-ABL transcript and new complex variant translocation involving the chromosomes 9, 12, 19 and 22.

### Acknowledgements

We thank SRL Laboratory and AMPATH (American Institute Of Pathology And Laboratory Sciences Pvt. Ltd. For their support. Their was no conflict of interest.

### References

- Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. *Nature*, 1985; 315:550-554.
- Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. *Blood*, 2000; 96:3343-3356.
- Al-Ali HK, Leiblein S, Kovacs I, Hennig E, Niederwieser D, Deininger MW. CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall. *Blood*, 2002; 100:1092-1093.
- Liu LG, Tanaka H, Ito K, Kyo T, Ito T, Kimura A. Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3. *Am J Hematol* 74: 268-272, 2003. 5. Snyder DS, McMahon R, Cohen SR and Slovak ML: Chronic myeloid leukemia with e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory. *Am J Hematol*. 2004; 75:92-95.
- Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L *et al*. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript. *Cancer Genet Cytogenet*, 2007; 174:111-115.
- Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. *Acta Haematol*, 2002; 107:76-94.
- Achkar Al W, Wafa A, Almedani S. BCR translocation to derivative chromosome 2: A new case of chronic myeloid leukemia with a complex variant translocation and Philadelphia chromosome. *Oncol Lett* 2010; 1:445-447.
- Shaffer L, Slovak M, Cambell L (eds): *ISCN: An International System for Human Cytogenetic Nomenclature*. S. Karger, Basel, 2009.
- Weise A, Mrasek K, Fickelscher I, Claussen U, Cheung SW, Cai WW *et al*. Molecular definition of high-resolution multicolor banding probes: first within the human DNA sequence anchored FISH banding probe set. *J HistochemCytochem*. 2008; 56:487-493.
- Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K *et al*. Microdissection based high resolution multicolor banding for all 24 human chromosomes. *Int J Mol Med*. 2002; 9:335-339.
- Mitelman F, Johansson B, Mertens F. (eds.): *Mitelman Database of Chromosome Aberrations in Cancer*. <http://cgap.nci.nih.gov/Chromosomes/Mitelman>, 2009.
- Starza La R, Testoni N, Lafage-Pochitaloff M, Ruggeri D, Ottaviani E, Perla G *et al*. Complex variant Philadelphia translocations involving the short arm of chromosome 6 in chronic myeloid leukemia. *Haematologica*. 2002; 87:143-147.
- Sandberg AA. *The Chromosomes In Human Cancer And Leukemia*. 2nd edition. Elsevier Science, New York, 1990, 151-172.
- Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. *Sem Oncol* 1998; 25:19-26.
- Que TH, Garcia Marco J, Ellis J, Matutes E, Brito Babapulle V, Boyle S *et al*. Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology. *Blood* 1993; 82:571-575.
- Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. *Nature* 1973; 24:290-295.
- Lifshitz B, Fainstein E, Marcelle C, Shtivelman E, Amson R, Gale RP and Canaani E: Bcr genes and transcripts. *Oncogene* 1988; 2:113-117.
- Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. *Blood* 1991; 77:874-878.
- Masuko M, Furukawa T, Abe T, Wada R, Maruyama S, Kitajima T *et al*. A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement. *Int J Hematol*. 2009; 90:230-234.